Drug · CHEMBL640
PROCAINAMIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PROCAINAMIDE. Drugs and targets, record CHEMBL640. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL640
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets10
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6336 |
| SCN11A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/11280 |
| SCN1A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6323 |
| SCN2A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6326 |
| SCN3A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6328 |
| SCN4A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6329 |
| SCN5A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6331 |
| SCN7A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6332 |
| SCN8A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6334 |
| SCN9A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6335 |
Source ChEMBL
Diseases7
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| ventricular fibrillation | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0000190 |
| atrial fibrillation | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0004981 |
| Ventricular arrhythmia | Approval | TTD | 2 | 1 | https://conductscience.org/library/drugs?q=HP_0004308 |
| Sudden death | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0001699 |
| Supraventricular tachycardia | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0004755 |
| ventricular tachycardia | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005477 |
| cardiac arrhythmia | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=EFO_0004269 |
Source Open Targets
Trials12
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01205529 | ST-segment Elevation as an AF Endophenotype | 161 | 2018-05-02 | procainamide | Its name | ClinicalTrials.gov | |
| NCT04234906 | Prevention of Post-Operative Cardiac Arrhythmias | Phase 4 | 870 | procainamide | Its name | ClinicalTrials.gov | |
| NCT04485195 | RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department | Phase 4 | 350 | procainamide | Its name | ClinicalTrials.gov | |
| NCT00383799 | Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia | Phase 4 | 302 | procainamide | Its name | ClinicalTrials.gov | |
| NCT00702117 | Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias | Phase 4 | 123 | procainamide | Its name | ClinicalTrials.gov | |
| NCT01994070 | Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation | Phase 3 | 86 | procainamide | Its name | ClinicalTrials.gov | |
| NCT02114528 | Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention | Phase 4 | 3 | procainamide | Its name | ClinicalTrials.gov | |
| NCT02575534 | Acute Mechanical Response to Anti-arrhythmic Drug Therapy | 0 | procainamide | Its name | ClinicalTrials.gov | ||
| NCT00000464 | Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) | Phase 3 | procainamide | Its name | ClinicalTrials.gov | ||
| NCT00000518 | Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) | Phase 3 | procainamide | Its name | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials10
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL640
GET https://conductscience.org/api/drugs/v1/CHEMBL640/targets